Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Accumulating epidemiological evidence shows that obesity is associated with an increased risk of several types of adult cancers, including endometrial cancer. Chronic hyperinsulinemia, a typical hallmark of diabetes, is one of the leading factors responsible for the obesity-cancer connection. Numerous cellular and circulating factors are involved in the biochemical chain of events leading from hyperinsulinemia and insulin resistance to increased cancer risk and, eventually, tumor development. Metformin is an oral anti-diabetic drug of the biguanide family used for treatment of type 2 diabetes. Recently, metformin was shown to exhibit anti-proliferative effects in ovarian and Type I endometrial cancer, although the mechanisms responsible for this non-classical metformin action remain unclear. The insulin-like growth factors (IGFs) play a prominent role in cancer biology and their mechanisms of action are tightly interconnected with the insulin signaling pathways. Given the cross-talk between the insulin and IGF signaling pathways, the aim of this study was to examine the hypothesis that the anti-proliferative actions of metformin in uterine serous carcinoma (USC) are potentially mediated via suppression of the IGF-I receptor (IGF-IR) pathway. Our results show that metformin interacts with the IGF pathway, and induces apoptosis and inhibition of proliferation and migration of USC cell lines with both wild type and mutant p53. Taken together, our results suggest that metformin therapy could be a novel and attractive therapeutic approach for human USC, a highly aggressive variant of endometrial cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin is shown to decrease insulin and IGF-1 levels and downregulate IIS in cancer cells”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Sarfstein et al. 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sarfstein, R., Belfiore, A., & Werner, H. (2010) · Cancers · doi:10.3390/cancers2020233 · Cited by 31 · cited 2×
“USPC-1 and USPC-2 cells were transfected as previously described [28,29].”
BackgroundMethodSelf-citationRetractedp53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“Part of these, seemingly, paradoxical results can be explained by the fact that Ishikawa cells are known to have mutations in the ras protooncogene, p53 [45] and pTen tumor suppressor gene, leading to constitutive phosphorylation of AKT [46].”
ResultThe phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 2×
“Deregulation of this fine balance might lead to metabolic growth related diseases, resistance to apoptosis, and increased proliferation [55,56].”
BackgroundRole of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“In vitro and in vivo studies showed increased peripheral insulin sensitivity and cancer growth inhibition by Ampk activation [27].”
BackgroundDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · cited 1×
“This was associated with decreased AKT activation [33], which led to reduced mTOR activation [23,34].”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 2×
“This was associated with decreased AKT activation [33], which led to reduced mTOR activation [23,34].”
BackgroundGuba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739 · cited 1×
“cell proliferation in a number of experimental systems [12–15].”
BackgroundA Detergent‐trypsin method for the preparation of nuclei for flow cytometric DNA analysis
Vindeløv, L. L., Christensen, I. J., & Nissen, N. I. (1983) · Cytometry · doi:10.1002/cyto.990030503 · Cited by 1,639
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Deregulation of this fine balance might lead to metabolic growth related diseases, resistance to apoptosis, and increased proliferation [55,56].”
BackgroundObesity, endogenous hormones, and endometrial cancer risk: a synthetic review.
Kaaks, R., Lukanova, A., & Kurzer, M. S. (2002) · PubMed · Cited by 1,199
Research works printed but not linked: 1
- Bruchim I, Attias Z, Werner H (2009) Targeting the IGF1 axis in cancer proliferation. Expert Opin Ther Targets 13: 1179– 1192. 19663648 · DOI
Cited by
Benefits of Metformin in Attenuating the Hallmarks of Aging
Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.001 · Cited by 766
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
“Metformin is reported to downregulate expression of insulin and IGF-1 receptors (230, 231) and reduces phosphorylation of insulin receptors (232) including IRS-1 (230, 233).”
BackgroundPolycystic ovary syndrome current status and future perspective
Naz, R. K. (2014) · Frontiers in Bioscience · doi:10.2741/e695 · Cited by 259
Wang, Y., Xu, W., Yan, Z., Zhao, W., Mi, J., Li, J., & Yan, H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0731-5 · Cited by 254
“In uterine serous carcinoma (USC), the antiproliferative action of metformin is mediated by suppression of the IGF-1 receptor pathway [20].”
Yan, L., Zhou, J., Gao, Y., Ghazal, S., Lu, L., Bellone, S., Yang, Y., Liu, N., Zhao, X., Santin, A. D., et al. (2015) · Oncogene · doi:10.1038/onc.2014.236 · Cited by 208
Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer
Brown, J. R., Chan, D. K., Shank, J. J., Griffith, K. A., Fan, H., Szulawski, R., Yang, K., Reynolds, R. K., Johnston, C., McLean, K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133247 · Cited by 198
“Metformin has been reported to inhibit epithelial-mesenchymal transition (EMT), IGF signaling, and selectively suppress cancer stemlike cell (CSC) growth (21-25).”
BackgroundTreatment strategies for endometrial cancer: current practice and perspective
Lee, Y. C., Lheureux, S., & Oza, A. M. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000338 · Cited by 193
Gritti, M., Würth, R., Angelini, M., Barbieri, F., Peretti, M., Pizzi, E., Pattarozzi, A., Carra, E., Sirito, R., Daga, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2617 · Cited by 135
“Further, in CSCs isolated from breast and lung carcinomas, or glioblastoma (GBM) [8, 9, 17-21], metformin-dependent cell proliferation arrest does not involve AMPK, but rather the down-regulation of IGF-1 signaling or inhibition of Akt [17, 22, 23].”
BackgroundSivalingam, V. N., Myers, J., Nicholas, S., Balen, A. H., & Crosbie, E. J. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu037 · Cited by 108
“Metformin was shown to induce G1 cell cycle arrest, increase apoptosis and reduce human telomerase reverse transcriptase expression (Cantrell et al., 2010; Sarfstein et al., 2013).”
AMP-Activated Protein Kinase Induces p53 by Phosphorylating MDMX and Inhibiting Its Activity
He, G., Zhang, Y.-W., Lee, J.-H., Zeng, S. X., Wang, Y. V., Luo, Z., Dong, X. C., Viollet, B., Wahl, G. M., & Lu, H. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00670-13 · Cited by 105
“Cells were treated with metformin or salicylate based on previous studies (44, 57, 58).”
MethodLaskov, I., Drudi, L. M., Beauchamp, M.-C., Yasmeen, A., Ferenczy, A. S., Pollak, M., & Gotlieb, W. H. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.06.014 · Cited by 108
Metformin: A Novel Biological Modifier of Tumor Response to Radiation Therapy
Koritzinsky, M. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.06.003 · Cited by 109
“Perhaps these dual roles for AMPK and p53 as growth-restricting but adaptation-promoting proteins contributes to the conflicting reports in regard to whether their activation promotes or mitigates antiproliferative and toxic effects of metformin (19, 24, 38, 53, 71, 82, 84-89).”
BackgroundThe IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches
Bruchim, I., Sarfstein, R., & Werner, H. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00076 · Cited by 98
“These data suggest that metformin therapy could be a novel and attractive therapeutic approach for endometrial cancer, in general, and USC, in particular (66).”
BackgroundSelf-citationMetformin use and gynecological cancers: A novel treatment option emerging from drug repositioning
Gadducci, A., Biglia, N., Tana, R., Cosio, S., & Gallo, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.06.006 · Cited by 91
Insulin induction instigates cell proliferation and metastasis in human colorectal cancer cells
Lu, C., Chu, P., Hsia, S., Wu, C., Tung, Y., & Yen, G. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3844 · Cited by 95
“A previous study demonstrated that the p53-dependent effect contributing to the proliferation in uterine serous carcinoma USPC-1 cells carrying wild-type p53 was induced by metformin through the downregulation of insulin/IGF-1 signaling (45).”
Wang, J., Huang, F., Bai, Z., Chi, B., Wu, J., & Chen, X. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160819851 · Cited by 85
“Many studies have shown that the activation of IGF-1R is involved in many cellular signaling pathways [15,16], as a tyrosine kinase-containing transmembrane receptor, up-regulation of IGF-IR will relate to several intracellular second messenger pathways, including the mitogen activated protein kinase (MAPK) and phosph…”
BackgroundMetformin limits the adipocyte tumor-promoting effect on ovarian cancer
Tebbe, C., Chhina, J., Dar, S. A., Sarigiannis, K. A., Giri, S., Munkarah, A. R., & Rattan, R. (2014) · Oncotarget · doi:10.18632/oncotarget.2012 · Cited by 85
“It has also been shown to inhibit tumors through indirect effects of lowering glucose, insulin and insulin growth factor-1 levels [35, 36].”
BackgroundSingle nucleotide polymorphisms of the FTO gene and cancer risk: an overview
Hernández-Caballero, M. E., & Sierra-Ramírez, J. A. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3817-y · Cited by 85
“Obesity is associated with insulin resistance and the hyperinsulinemia compensatory increase in the production of growth factors, which in turn stimulates mitogenesis and consequently carcinogenesis [7], multiple signaling pathways, oxidative stress and inflammatory processes.”
BackgroundMeasuring the biological effect of presurgical metformin treatment in endometrial cancer
Sivalingam, V. N., Kitson, S., McVey, R., Roberts, C., Pemberton, P., Gilmour, K., Ali, S., Renehan, A. G., Kitchener, H. C., & Crosbie, E. J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.453 · Cited by 82
“…studies have demonstrated a growth static effect of metformin on breast, prostate, ovarian and EC cell lines, effected both through alterations in glucose metabolism and inhibition of the PI3K-AKT-mTOR signalling pathway (Zakikhani et al, 2006, 2010; Cantrell et al, 2010; Sarfstein et al, 2013).”
BackgroundExploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases
Du, M., Gao, Q.-Y., Liu, C., Bai, L.-Y., Li, T. X., & Wei, F. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.838173 · Cited by 88
Metformin as a Therapeutic Target in Endometrial Cancers
Lee, T. Y., Martinez‐Outschoorn, U., Schilder, R. J., Kim, C. H., Richard, S. D., Rosenblum, N. G., & Johnson, J. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00341 · Cited by 77
“Other well-described effects of AMPK activation include phosphorylation and inactivation of AcetylCoA carboxylase (ACC) leading to downregulation of fatty acid synthesis (83, 91) as well as inhibition of signaling via the insulin-like growth factor-1 receptor (IGF-1R).”
BackgroundInfluentialInsulin-like growth factor-1 signaling in renal cell carcinoma
Tracz, A., Szczylik, C. A., Porta, C., & Czarnecka, A. M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2437-4 · Cited by 76
“Exception is metformin an oral anti-diabetic drug has a RCCprotective effect as it interacts with the IGF signaling pathway which results in inhibition of proliferation and apoptosis regardless the p53 status [99].”
BackgroundOld drug, new trick: Repurposing metformin for gynecologic cancers?
Febbraro, T., Lengyel, E. R., & Romero, I. L. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.10.011 · Cited by 75
“Consistent with this signaling cascade, endometrial cancer cells treated with metformin show a dose dependent increase in AMPK activation and a decrease in mTOR signaling [46,59,47,49,50].”
BackgroundMetformin: From Diabetes to Cancer—Unveiling Molecular Mechanisms and Therapeutic Strategies
Amengual-Cladera, E., Morla-Barcelo, P. M., Morán-Costoya, A., Valle, A., Pons, D. G., Sastre‐Serra, J., Roca, P., & Nadal‐Serrano, M. (2024) · Biology · doi:10.3390/biology13050302 · Cited by 86
“Repurposing metformin for cancer treatment holds promise for rapid progress in this regard, given its approved status, well-established pharmacokinetics, and tolerability profile.”
Würth, R., Barbieri, F., & Florio, T. (2014) · BioMed Research International · doi:10.1155/2014/126586 · Cited by 75
“In light of these findings, the potential antitumor effects of metformin have been evaluated in numerous in vitro studies on several cancer models including breast [65, 66], endometrial [67, 68], ovarian [69, 70], pancreatic [71, 72], lung [73], prostate [74], head and neck carcinomas [75], acute myeloid leukemia [76]…”
BackgroundShao, R., Li, X., Feng, Y., Lin, J.-F., & Billig, H. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-41 · Cited by 71
“It has been reported that metformin decreases local androgen synthesis in human ovarian cells [79,80], increases GLUT4 expression in endometrial cells from PCOS women with hyperinsulinemia [81], inhibits cell proliferation [36,37], and induces cell cycle arrest and apoptosis [35] in type I EC cells, all of which have…”
BackgroundInvestigational IGF1R inhibitors in early stage clinical trials for cancer therapy
Werner, H., Sarfstein, R., & Bruchim, I. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1694660 · Cited by 66
“that metformin interacts with the IGF pathway and induces apoptosis and inhibition of proliferation and migration of uterine serous carcinoma cell lines [131].”
BackgroundSelf-citationKitson, S., Maskell, Z., Sivalingam, V. N., Allen, J. L., Ali, S., Burns, S., Gilmour, K., Latheef, R., Slade, R. J., Pemberton, P. W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3339 · Cited by 63
“It indirectly lowers levels of insulin, itself a potent stimulator of endometrial cancer growth (9) and downregulates expression of insulin and related growth factors receptors (10–12), inhibits phosphorylation and activation of the insulin-like growth factor 1 receptor (10), and increases expression of insulin-like g…”
BackgroundTargeting obesity-related dysfunction in hormonally driven cancers
Rubinstein, M. M. Z., Brown, K. A., & Iyengar, N. M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01393-y · Cited by 62
Li, X., Guo, Y.-R., Lin, J.-F., Feng, Y., Billig, H., & Shao, R. (2014) · Journal of Cancer · doi:10.7150/jca.8009 · Cited by 64
“Recently, Sarfstein and colleagues have reported that treatment with metformin decreases cell proliferation and increases apoptosis in uterine serous carcinoma through inhibition of the insulin/IGF-I signaling pathway [48].”
BackgroundRevisiting Glycogen in Cancer: A Conspicuous and Targetable Enabler of Malignant Transformation
Khan, T., Sullivan, M. A., Gunter, J. H., Kryza, T., Lyons, N., He, Y., & Hooper, J. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.592455 · Cited by 63
Molecular targets of metformin antitumor action
Sośnicki, S., Kapral, M., & Węglarz, L. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.04.021 · Cited by 59
Antiproliferative Effect of Metformin on the Endometrium - a Clinical Trial
Tabrizi, A. D., Sayyah-Melli, M., Foroughi, M., Ghojazadeh, M., & Bidadi, S. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.23.10067 · Cited by 57
“…association with effective antiproliferative activity in endometrial hyperplasia, low grade endometrial carcinoma and even in endometrial serous carcinoma cell line (Perino et al., 1987a; 1997b; Shen et al., 2008; Shen et al., 2008; Prat et al., 2009; Sarfstein et al., 2013; Shafiee et al., 2013).”
BackgroundIntermittent and Periodic Fasting, Hormones, and Cancer Prevention
Salvadori, G., Mirisola, M. G., & Longo, V. D. (2021) · Cancers · doi:10.3390/cancers13184587 · Cited by 49
Gong, J., Kelekar, G., Shen, J., Shen, J., Kaur, S., & Mita, M. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0423-z · Cited by 60
“These effects were associated with G1-S stage cell cycle arrest dependent on cyclin D1 downregulation and increased apoptosis in specific cancer cell lines highlighting that metformin’s antiproliferative effects are mediated, in part, by insulin and IGF-1 signaling [57].”
BackgroundJustice, J. N., Gubbi, S., Kulkarni, A. S., Bartley, J. M., Kuchel, G. A., & Barzilai, N. (2020) · GeroScience · doi:10.1007/s11357-020-00261-6 · Cited by 54
Zou, J., Hong, L., Luo, C., Li, Z., Zhu, Y., Huang, T., Zhang, Y., Yuan, H., Hu, Y., Wen, T., et al. (2016) · Cancer Science · doi:10.1111/cas.13083 · Cited by 57
Anti-Aging Effects of Calorie Restriction (CR) and CR Mimetics Based on the Senoinflammation Concept
Kim, D. H., Bang, E., Jung, H. J., Noh, S. G., Yu, B. P., Choi, Y. J., & Chung, H. Y. (2020) · Nutrients · doi:10.3390/nu12020422 · Cited by 58
Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.
Guo, H., Kong, W., Zhang, L., Han, J., Clark, L. H., Yin, Y., Fang, Z., Sun, W., Wang, J., Gilliam, T. P., et al. (2019) · PubMed Central · Cited by 59
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy
Ezewuiro, O., Grushko, T. A., Kocherginsky, M., Habis, M., Hurteau, J. A., Mills, K. A., Hunn, J., Olopade, O. I., Fleming, G. F., & Romero, I. L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147145 · Cited by 50
Arrieta, O., Varela-Santoyo, E., Soto-Perez-de-Celis, E., Sánchez-Reyes, R., De la Torre-Vallejo, M., Muñiz-Hernández, S., & Cardona, A. F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2658-6 · Cited by 51
Insulin Resistance and Endometrial Cancer: Emerging Role for microRNA
Sidorkiewicz, I., Jóźwik, M., Niemira, M., & Kretowski, A. J. (2020) · Cancers · doi:10.3390/cancers12092559 · Cited by 60
“In contrast, metformin (an oral antidiabetic drug of the biguanide family used for the treatment of T2DM) is known to interact with the IGF pathway, induces apoptosis, and inhibits proliferation and migration of EC cells [68].”
BackgroundMatthews, Q., Isabelle, M., Harder, S. J., Smazynski, J., Beckham, W., Brolo, A. G., Jirasek, A. I., & Lum, J. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135356 · Cited by 50
“Thus, metformin at the concentrations used here can reduce p-GSK-3β levels [36].”
BackgroundValaee, S., Yaghoobi, M. M., & Shamsara, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174486 · Cited by 49
DPPIV promotes endometrial carcinoma cell proliferation, invasion and tumorigenesis
Yang, X., Zhang, X., Wu, R., Huang, Q., Jiang, Y. X., Qin, J., Yao, F., Jin, G., & Zhang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.14412 · Cited by 47
“Several studies have shown a correlation between IGF components and endometrial cancer risk [55, 56].”
BackgroundSchwartsburd, P. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00218 · Cited by 47
Kyo, S., & Nakayama, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176073 · Cited by 46
The Influence of Metformin on IGF-1 Levels in Humans: A Systematic Review and Meta-Analysis
Yang, X., Kord-Varkaneh, H., Talaei, S., Clark, C. C. T., Zanghelini, F., Tan, S. C., Zarezadeh, M., Mousavi, S. M., Rahmani, J., & Zhang, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104588 · Cited by 43
Hao, B., Xiao, Y., Song, F., Long, X., Huang, J., Tian, M., Deng, S., & Wu, Q. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3346 · Cited by 41
“Previous studies have reported that AMPK and p53 serve important roles in metformin-mediated cell growth arrest and migratory inhibition (21,22,33).”
RetractedRepurposing metformin for the treatment of gastrointestinal cancer
Júnior, A. D. D. C., Bragagnoli, A. S. C., Costa, F. O., & Carvalheira, J. B. C. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1883 · Cited by 46
Molecular cues on obesity signals, tumor markers and endometrial cancer
Daley-Brown, D. S., Oprea‐Ilies, G., Lee, R., Pattillo, R. A., & Gonzalez-Perez, R. R. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0049 · Cited by 43
“In addition to normalizing insulin levels, metformin has been shown to downregulate IGF-1R and upregulate IGF binding protein-1 in EmCa cell lines, and inhibit IGF-1 pathway in type I EmCa [42].”
Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection
Vella, V., Malaguarnera, R., Nicolosi, M. L., Morrione, A., & Belfiore, A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118522 · Cited by 43
Metformin as a new anti-cancer drug in adrenocortical carcinoma
Poli, G., Cantini, G., Armignacco, R., Fucci, R., Santi, R., Canu, L., Nesi, G., Mannelli, M., & Luconi, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10421 · Cited by 43
“In particular, this drug interferes with the insulin/IGF-1R system in tumor cells [8, 17] as shown in pancreatic [10, 18, 19], breast [20, 21], endometrial [22, 23], prostate [24] and lung [25] cancers.”
BackgroundInhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells
Du, J., Shi, H.-R., Ren, F., Wang, J.-L., Wu, Q., Li, X., & Zhang, R. (2017) · BMC Cancer · doi:10.1186/s12885-017-3840-1 · Cited by 41
“Similarly, a previous study has shown that metformin interacts with the IGF pathway, and induces apoptosis and inhibition of proliferation and migration of uterine serous carcinoma cell lines [22], so this led us to investigate the mechanism of metformin increasing resistance in ovarian cells with attention on MRP2.”
BackgroundEffects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines
Nozhat, Z., Mohammadi‐Yeganeh, S., Azizi, F., Zarkesh, M., & Hedayati, M. (2018) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-018-0208-2 · Cited by 42
Metformin suppresses breast cancer growth via inhibition of cyclooxygenase‑2
Shi, B., Hu, X., He, H., & Fang, W. (2021) · Oncology Letters · doi:10.3892/ol.2021.12876 · Cited by 42
Metformin Impairs Glutamine Metabolism and Autophagy in Tumour Cells
Saladini, S., Aventaggiato, M., Barreca, F., Morgante, E., Sansone, L., Russo, M. A., & Tafani, M. (2019) · Cells · doi:10.3390/cells8010049 · Cited by 42
Wen, Q., Zhao, Z., Wen, J., Zhou, J., Wu, J., Lei, S., & Miao, Y. (2019) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2019.03.029 · Cited by 37
O’Rawe, M., Wickremesekera, A., Pandey, R., Young, D., Sim, D. A., Fitzjohn, T. P., Burgess, C., Kaye, A. H., & Tan, S. T. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.11.023 · Cited by 39
Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin
Sivalingam, V. N., Latif, A., Kitson, S., McVey, R. J., Finegan, K. G., Marshall, K. M., Lisanti, M. P., Sotgia, F., Stratford, I. J., & Crosbie, E. J. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0627-y · Cited by 36
Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk
Lauretta, R., Lanzolla, G., Vici, P., Mariani, L., Moretti, C., & Appetecchia, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/8671762 · Cited by 36
“Thus, a pivotal biological pathway leading to endometrial cancermay be theoretically controlled by metformin, to reduce the risk of EH progression [174].”
BackgroundAssociation between FTO gene polymorphisms and breast cancer: the role of estrogen
Gholamalizadeh, M., Jarrahi, A. M., Akbari, M. E., Bourbour, F., Mokhtari, Z., Salahshoornezhad, S., & Doaei, S. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1730176 · Cited by 35
“Moreover, some contradictory results may be due to the racial differences in the study groups [38].”
BackgroundResultKim, S.-J., Lim, J., Lee, J. N., Choe, S., Kim, Y., Song, S. R., Cho, M., So, H., & Park, R. (2014) · Toxicology · doi:10.1016/j.tox.2014.01.013 · Cited by 37
Suhaimi, N.-A. M., Phyo, W. M., Yap, H. Y., Choy, S. H. Y., Wei, X., Choudhury, Y., Tan, W. J., Tan, L. A. P. Y., Foo, R., Tan, S. H. S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0793 · Cited by 37
“Growth inhibition of 5-FU and metformin on cancer cell lines Metformin has been reported to preferentially inhibit the growth of p53-mutant cells by forcing a metabolic burden that result in selective toxicity (9, 21, 22).”
BackgroundMetformin and Gynecologic Cancers
Stine, J. E., & Bae-Jump, V. L. (2014) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000092 · Cited by 34
Kumar, H., Chakrabarti, A., Sarma, P., Modi, M., Banerjee, D., Radotra, B. D., Bhatia, A., & Medhi, B. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106348 · Cited by 34
Costa, D., Gigoni, A., Würth, R., Cancedda, R., Florio, T., & Pagano, A. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-59 · Cited by 34
“However, several studies suggested that mechanisms, others than AMPK activation, could mediate antiproliferative activity of metformin [39-41].”
BackgroundMetformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC
Cao, H., Dong, W., Qu, X. H., Shen, H., Xu, J., Zhu, L., Liu, Q., & Du, J. (2016) · Scientific Reports · doi:10.1038/srep31072 · Cited by 32
Jiménez‐Vacas, J. M., Herrero‐Aguayo, V., Montero‐Hidalgo, A. J., Sáez-Martínez, P., Gómez‐Gómez, E., León‐González, A. J., Fuentes-Fayos, A. C., Yubero‐Serrano, E. M., Requena-Tapia, M. J., López, M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa877 · Cited by 28
Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells
Scordamaglia, D., Cirillo, F., Talia, M., Santolla, M. F., Rigiracciolo, D. C., Muglia, L., Zicarelli, A., Rosis, S. D., Giordano, F., Miglietta, A., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03463-y · Cited by 30
Conza, D., Mirra, P., Calı̀, G., Insabato, L., Fiory, F., Bèguinot, F., & Ulianich, L. (2021) · Cells · doi:10.3390/cells10051067 · Cited by 27
Efficacy of Metformin as Adjuvant Therapy in Metastatic Breast Cancer Treatment
Essa, N. M., Salem, H. F., Elgendy, M. O., Gabr, A., Omran, M. M., Hassan, N. A., Tashkandi, H., Harakeh, S., & Boshra, M. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195505 · Cited by 27
“Moreover, several studies have confirmed that metformin significantly contributes to inducing apoptosis and inhibiting the proliferation of cells through the interaction with the IGF pathway [18].”
BackgroundParish, A. J., & Swindell, W. R. (2022) · Aging Cell · doi:10.1111/acel.13733 · Cited by 27
“…mTORC1 (Howell et al., 2017; Kalender et al., 2010; Martin- Montalvo et al., 2013), activates SIRT1 (Cuyàs et al., 2018), decreases IGF- 1 levels (Sarfstein et al., 2013), reduces inflammation, attenuates cellular senescence (Moiseeva et al., 2013), enhances autophagy (Bharath et al., 2020), and…”
BackgroundFeng, H., Zang, L., Zhao, Z.-X., & Kan, Q. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1614 · Cited by 28
Research progress on aging mechanism and drugs and the role of stem cells in anti-aging process
Zhang, Y., Li, Q., Niu, Y., Wei, K., Wang, X., Niu, B., & Zhang, L. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112248 · Cited by 28
Cao, H., Dong, W., Shen, H., Xu, J., Zhu, L., Liu, Q., & Du, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135844 · Cited by 24
“Despite of its metabolic effects, metformin was reported to affect IGF-1R and the downstream signaling pathways [17,38], although the precise mechanism is not yet well illustrated.”
BackgroundFarkhondeh, T., Amirabadizadeh, A., Aramjoo, H., Llorens, S., Roshanravan, B., Saeedi, F., Talebi, M., Shakibaei, M., & Samarghandian, S. (2021) · Current Oncology · doi:10.3390/curroncol28020134 · Cited by 27
“Research (in-vitro) has indicated that metformin inhibits the growth of various human cancer cell lines by controlling the PI3K-AKT-mTOR signaling pathway as well as glucose metabolism [7,8].”
BackgroundMachado, A. D. B., dos Reis, V. M. S. F., Weber, S. F., Jauckus, J., Brum, I. S., Corleta, H. V. E., Strowitzki, T., Capp, E., & Germeyer, A. (2016) · Oncology Letters · doi:10.3892/ol.2016.5041 · Cited by 23
“Additionally, experimental studies revealed that metformin is an effective antiestrogenic agent, inhibiting cell proliferation and leading to growth arrest, as well as inducing apoptosis in EC (17,20-22).”
Clinical benefits of metformin in gynecologic oncology
Imai, A., Ichigo, S., Matsunami, K., TAKAGI, H., & Yasuda, K. (2015) · Oncology Letters · doi:10.3892/ol.2015.3262 · Cited by 24
“Investigating uterine serous carcinoma, an aggressive subtype of endometrial cancer, Sarfstein et al (57) demonstrated that metformin interacted with the IGF pathway, inducing apoptosis and inhibition of proliferation and migration of uterine serous carcinoma cell lines with wild-type or mutant p53.”
Franchi, M., Asciutto, R., Nicotra, F., Merlino, L. G., Vecchia, C. L., Corrao, G., & Bosetti, C. (2016) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000235 · Cited by 23
“Experimental studies (Cantrell et al., 2010; Sarfstein et al., 2013; Febbraro et al., 2014; Mitsuhashi et al., 2014; Xie et al., 2014) and a few epidemiological investigations (Ko et al., 2014; Nevadunsky et al., 2014) have suggested a favorable role of metformin in endometrial cancer recurrence…”
BackgroundInfluentialMechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk
Lan, W.-H., Lin, T., Yeh, J.-A., Feng, C., Hsu, J., Lin, H., Kuo, C., & Lai, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214163 · Cited by 25
Metformin exposure and disseminated disease in patients with colorectal cancer
Spillane, S., Bennett, K., Sharp, L., & Barron, T. I. (2014) · Cancer Epidemiology · doi:10.1016/j.canep.2013.12.003 · Cited by 21
Zhu, P., Shen, L., Ren, Q., Zeng, Q., & Xiaocui, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.587420 · Cited by 23
Metformin in gynecological disorders: pathogenic insights and therapeutic implications
Nie, P., Wang, M., Mo, Y., Zhou, H., Zha, Q., Lash, G. E., & Li, P. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1526709 · Cited by 21
Gu, C., Cheng, J., Zhang, B., Yang, S., Xie, F., Sun, J., Huang, L., Yu, J., & Li, M. (2017) · Europe PMC (PubMed Central) · Cited by 21
Walcott, F. L., Wang, P., Bryla, C., Huffstutler, R. D., Singh, N., Pollak, M., Khincha, P. P., Savage, S. A., Mai, P. L., Dodd, K. W., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa063 · Cited by 21
“Similarly, metformin interacts with the IGF pathway in the presence of either wild-type or mutant TP53 (37).”
BackgroundCircadian medicine for aging attenuation and sleep disorders: Prospects and challenges
Banerjee, S., & Ray, S. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102387 · Cited by 18
Shirooie, S., Sahebgharani, M., Esmaeili, J., & Dehpour, A. R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27125 · Cited by 18
“Sarfstein et al. (2013) demonstrated that metformin could inhibit mTOR signaling pathway in a AMPK‐ independent manner via inhibition of PRAS40 phosphorylation (negative regulator of mTOR) in uterine serous carcinoma cells.”
BackgroundLemon, L. S., Orr, B. C., Modugno, F., Buckanovich, R. J., Coffman, L. G., Edwards, R. P., & Taylor, S. E. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.01.022 · Cited by 15
Brown, R. E., Buryanek, J., Tammisetti, V. S., McGuire, M. F., & Smith, K. C. (2016) · Oncotarget · doi:10.18632/oncotarget.9508 · Cited by 18
Nan, X., Wang, J., Cheng, H., Yin, Z., Sheng, J., Qiu, B., Lau, C. C., Yustein, J. T., Zhao, H., & Wong, S. T. C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.034 · Cited by 15
Perspectives of metformin use in endometrial cancer and other gynaecological malignancies
Barczyński, B., Frąszczak, K., & Kotarski, J. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.2005072 · Cited by 15
“Notably, metformin use was linked with downregulation of insulin/insulin growth factor receptor pathway irrespective to p53 mutation status [45,46].”
BackgroundEnhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins
Almeida-Nunes, D. L., Silvestre, R., Dinis‐Oliveira, R. J., & Ricardo, S. A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010323 · Cited by 17
“In OC mice models, metformin treatment decreases IGF-1 levels [108] and the IGF-1 signaling pathway in uterine serous carcinoma [102].”
BackgroundThe Dual Role of Metformin: Repurposing an Antidiabetic Drug for Cancer Therapy
Barbosa, F., Cunha, A., Barbosa, J., Faria, J., & Queirós, O. (2025) · Applied Sciences · doi:10.3390/app152111576 · Cited by 13
Current trends and future prospects of drug repositioning in gastrointestinal oncology
Fatemi, N., Karimpour, M., Bahrami, H., Zali, M. R., Chaleshi, V., Riccio, A., Mojarad, E. N., & Totonchi, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1329244 · Cited by 19
Bae-Jump, V. L., Sill, M. W., Gehrig, P. A., Merker, J. D., Corcoran, D. L., Pfefferle, A. D., Hayward, M. C., Walker, J. L., Hagemann, A. R., Waggoner, S. E., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.03.003 · Cited by 12
PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer
Fares, F., Berger, L., Girsh, E., Kakun, R. R., Ghannam-Shahbari, D., Tabach, Y., Zohar, Y., Gottlieb, E., & Perets, R. (2021) · Oncogene · doi:10.1038/s41388-021-01925-z · Cited by 11
Metformin for lung cancer prevention and improved survival: a novel approach
Roos, J. F., Qudsi, M., Samara, A., Rahim, M. M., Al-Bayedh, S. A., & Ahmed, H. (2018) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000442 · Cited by 11
“However, through the downregulation of IGF-1R and the reduction of mutated p53 levels, metformin is able to reduce proliferation and cancer cell migration (Sarfstein et al., 2013).”
BackgroundLetrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Konstantinopoulos, P. A., Zhou, N., Penson, R. T., Le, T. V., Campos, S. M., Krasner, C. N., Wright, A. A., Porter, R. L., Horowitz, N., Bouberhan, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67087-8 · Cited by 12
Şahin, E., Şahin, M. E., Dolanbay, M., Özçelik, B., Akgün, H., & Saatçı, Ç. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1409708 · Cited by 11
Metadata
- Authors
- Sarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., & Werner, H.
- Affiliations
- Tel Aviv University (IL)
- Meir Medical Center (IL)
- Corresponding author
- Werner, Haim
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-19
- Volume
- 8
- Issue
- 4
- Pages
- e61537
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3631250
- OpenAlex
- W2009665800
- Cited by
- 150
- References
- 58
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 14 · 2020: 14 · 2019: 14 · 2018: 11 · 2017: 10 · 2016: 16 · 2015: 11 · 2014: 22 · 2013: 3
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- metformin, uterine serous carcinoma, IGF-1 receptor, p53, apoptosis, cell proliferation, cell migration, endometrial cancer, hyperinsulinemia, biguanides
- MeSH terms
- Forkhead Box Protein O1, Glycogen Synthase Kinase 3 beta, Adenylate Kinase, Cell Cycle, Cell Movement, Cell Survival, Female, Humans, Insulin, Insulin-Like Growth Factor I, Metformin, Phosphorylation, Promoter Regions, Genetic, Receptor, Insulin, Uterine Neoplasms, Signal Transduction, Down-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Endometrial Neoplasms, Apoptosis, Receptor, IGF Type 1, Cystadenocarcinoma, Serous, Glycogen Synthase Kinase 3, Cell Line, Tumor, Cell Proliferation, Forkhead Transcription Factors, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.